Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Biomolecules · 20.01.2023 · 13 (2) · 210
DOI: 10.3390/biom13020210 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 20.01.2023. Verfasst von Zhenfang Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetic and Developmental Biology, School of Medicine, Southeast University, Nanjing 210003, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Association For Cancer Research, Fundamental Research Funds for the Central Universities, AACR-AstraZeneca Lung Cancer Research Fellowship.
Abstract (Originalsprache)
Oncogenic mutations within the EGFR kinase domain are well-established driver mutations in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) specifically targeting these mutations have improved treatment outcomes for patients with this subtype of NSCLC. The selectivity of these targeted agents is based on the location of the mutations within the exons of the EGFR gene, and grouping mutations based on structural similarities has proved a useful tool for conceptualizing the heterogeneity of TKI response. Structure-based analysis of EGFR mutations has influenced TKI development, and improved structural understanding will inform continued therapeutic development and further improve patient outcomes. In this review, we summarize recent progress on targeted therapy strategies for patients with EGFR-mutant NSCLC based on structure and function analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetic and Developmental Biology, School of Medicine, Southeast University, Nanjing 210003, China.
- School of Life Science and Technology, Southeast University, Nanjing 210018, China.
- BioSpatula LLC, Telford, PA 18969, USA.
- Department of Radiotherapy, Nanjing Chest Hospital, Nanjing Medical University Affiliated Brain Hospital, Nanjing 210029, China.
- Department of Respiratory Medicine and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
- Department of Thoracic Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 31002…
ORCID-Profile: Zhenfang Du
Förderung
- American Association For Cancer Research
- Fundamental Research Funds for the Central Universities
- AACR-AstraZeneca Lung Cancer Research Fellowship
- Summer Research Trainee Program
Zitieren
APA
Du, Z., Sun, J., Zhang, Y., Hesilaiti, N., Xia, Q., Cui, H., Fan, N., & Xu, X. (2023). Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer. Biomolecules, 13(2), 210. https://doi.org/10.3390/biom13020210
Vancouver
Du Z, Sun J, Zhang Y, Hesilaiti N, Xia Q, Cui H, et al. Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer. Biomolecules. 2023;13(2):210. doi:10.3390/biom13020210
BibTeX
@article{Du2023,
author = {Du, Zhenfang and Sun, Jinghan and Zhang, Yunkai and Hesilaiti, Nigaerayi and Xia, Qi and Cui, Heqing and Fan, Na and Xu, Xiaofang},
title = {Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {2},
pages = {210},
doi = {10.3390/biom13020210}
}
EUVIMED